[
  {
    "ts": null,
    "headline": "Amgen: Imdelltra Data And Q1 Results Impress",
    "summary": "Amgen beat Q1 estimates with strong margins driven by Blincyto, Prolia, and standout Imdelltra growth, plus strength in obesity. See why AMGN stock is a buy.",
    "url": "https://finnhub.io/api/news?id=e55e0165653634dfa6e0f1d12f98c2dbc180b62d6101deb1987ab0a63f0513ca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749897000,
      "headline": "Amgen: Imdelltra Data And Q1 Results Impress",
      "id": 135271702,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389349379/image_1389349379.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Amgen beat Q1 estimates with strong margins driven by Blincyto, Prolia, and standout Imdelltra growth, plus strength in obesity. See why AMGN stock is a buy.",
      "url": "https://finnhub.io/api/news?id=e55e0165653634dfa6e0f1d12f98c2dbc180b62d6101deb1987ab0a63f0513ca"
    }
  }
]